These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer. Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutics in development for prostate cancer. Harzstark AL; Small EJ Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474 [TBL] [Abstract][Full Text] [Related]
6. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Tuyaerts S; Aerts JL; Corthals J; Neyns B; Heirman C; Breckpot K; Thielemans K; Bonehill A Cancer Immunol Immunother; 2007 Oct; 56(10):1513-37. PubMed ID: 17503040 [TBL] [Abstract][Full Text] [Related]
7. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Moschella F; Proietti E; Capone I; Belardelli F Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466 [TBL] [Abstract][Full Text] [Related]
8. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Baxevanis CN; Perez SA; Papamichail M Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409 [TBL] [Abstract][Full Text] [Related]
9. [Cancer therapy by using bispecific antibody]. Azuma A; Niitani H; Okumura K Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618 [TBL] [Abstract][Full Text] [Related]
11. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Khawli LA; Hu P; Epstein AL Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951 [TBL] [Abstract][Full Text] [Related]
12. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? Shurin MR; Gregory M; Morris JC; Malyguine AM Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111 [TBL] [Abstract][Full Text] [Related]
13. A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro. Yano Y; Ueda Y; Itoh T; Fuji N; Okugawa K; Naito K; Imura K; Kohara J; Hayashi T; Nakane K; Matsuura Y; Kawai K; Yamagishi H Oncol Rep; 2006 Jul; 16(1):147-52. PubMed ID: 16786138 [TBL] [Abstract][Full Text] [Related]
14. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies. Kim S; Haas GP; Hillman GG Cytokines Mol Ther; 1996 Mar; 2(1):13-9. PubMed ID: 9384685 [TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy for cancer--modern immunologic strategies in oncology]. Halama N; Zoernig I; Jäger D Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564 [TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862 [TBL] [Abstract][Full Text] [Related]
18. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. O'Malley BW; Li D; McQuone SJ; Ralston R Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147 [TBL] [Abstract][Full Text] [Related]
19. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells]. Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759 [TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy of cancer with interleukin-2 and with interleukin-2 activated cells]. Osanto S; Brand A; van Rood JJ; Cleton FJ Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1392-5. PubMed ID: 2677758 [No Abstract] [Full Text] [Related] [Next] [New Search]